Dyspepsia

Medical Clinics of North America

Volumn 98, Issue 3, 2014, Pages 549-564

  Overland, Maryann Katherine ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Functional dyspepsia; Gastroesophageal reflux disease; Helicobacter pylori test and treat; Peptic ulcer disease

Indexed keywords

ACTIVATED CARBON; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MAGNESIUM; MAGNESIUM OXIDE; PROKINETIC AGENT; SIMETHICONE;

ACUPUNCTURE; CHOLELITHIASIS; CHRONIC CHOLECYSTITIS; CHRONIC PANCREATITIS; DUODENUM MOTILITY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; IRRITABLE COLON; MESENTERIC ISCHEMIA; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ESOPHAGITIS; REVIEW; STOMACH EMPTYING;

FUNCTIONAL DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE; HELICOBACTER PYLORI TEST AND TREAT; PEPTIC ULCER DISEASE;

DIAGNOSIS, DIFFERENTIAL; DYSPEPSIA; GASTROINTESTINAL DISEASES; HUMANS;

EID: 84899063210     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.01.007     Document Type: Review

References (68)

1. Van Zanten S., Flook N., Chiba N. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000, 162(Suppl 12):S3-S23.
2. Zagari R., Fuccio L., Bazzoli F. Investigating dyspepsia. BMJ 2008, 337:11400.
3. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143:1179-1187.
4. Haycox A., Einarson T., Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999, 231(Suppl):38-47.
5. Piessevaux H., De Winter B., Louis E., et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009, 21:378-388.
6. Sander G.B., Mazzoleni L.E., Francesconi C.F., et al. Influence of organic and functional dyspepsia on work productivity: the HEROES-DIP study. Value Health 2011, 14:S126-S129.
7. Talley N.J., American Gastroenterological Association American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005, 129(5):1753-1755.
8. National Institute for Health and Clinical Excellence (NICE) Dyspepsia: managing dyspepsia in adults in primary care 2004, National Institute for Health and Clinical Excellence (NICE), London.
9. Tack J., Talley N.J., Camilleri M., et al. Functional gastroduodenal disorders. Gastroenterology 2006, 130(5):1466-1479.
10. Xiao Y.L., Peng S., Tao J., et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010, 105:2626-2631.
11. Nandurkar S., Talley N.J., Xia H., et al. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med 1998, 158:1427-1433.
12. Pike B., Porter C., Sorrell T., et al. Acute gastroenteritis and the risk of functional dyspepsia: a systemic review and meta-analysis. Am J Gastroenterol 2013, 108(10):1558-1563.
13. Talley N.J., Locke G.R., Lahr B.D., et al. Functional dyspepsia, delayed gastric emptying and impaired quality of life. Gut 2006, 55:933-939.
14. Sha W., Pasricha P.J., Chen J.D. Correlations among electrogastrogram, gastric dysmotility, and duodenal dysmotility in patients with functional dyspepsia. JClin Gastroenterol 2009, 43:716-722.
15. Perri F., Clemente R., Festa V., et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998, 93:2082-2088.
16. Kindt S., Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006, 55(12):1685-1691.
17. Quartero A.O., de Wit N.J., Lodder A.C., et al. Disturbed solid phase gastric emptying in functional dydpepsia: a meta-analysis. Dig Dis Sci 1998, 43:2028-2032.
18. Stanghellini V., Tossetti C., Paternico A., et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110:1036-1042.
19. Führer M., Vogelsang H., Hammer J. Aplacebo-controlled trial of an oral capsaicin load in patients with functional dyspepsia. Neurogastroenterol Motil 2011, 23(10):918-928.
20. Li X., Cao Y., Wong R.K., et al. Visceral and somatic sensory function in functional dyspepsia. Neurogastroenterol Motil 2013, 25(3):246-253.
21. Holtmann G., Siffert W., Haag S., et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004, 126:971-979.
22. Mearin F., Perez-Oliveras M., Perello A., et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow up cohort study. Gastroenterology 2005, 129:98-104.
23. Kindt S., Tertychnyy A., de Hertogh G., et al. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil 2009, 21:832-838.
24. Koloski N.A., Jones M., Kalantar J., et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012, 61:1284-1290.
25. Talley N.J., Zinmeister A.R., Schleck C.D., et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992, 102:1259-1268.
26. Konekes K., Jackson J.L., Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcomes. Am J Med 1997, 103:339-347.
27. Clauwaert N., Jones M.P., Holvoet L., et al. Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal?. Neurogastroenterol Motil 2012, 24:1088-1095.
28. Wilson J. Gastroesophageal reflux disease. Ann Intern Med 2008, 149(3). ITC(2)1-15.
29. Tefera L., Fein M., Ritter M.P., et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?. Am Surg 1997, 63:933-936.
30. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200.
31. Fass P., Ofman I.J., Samplinter R.E., et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastrooesophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther 2000, 14:389-396.
32. Schenk B.E., Kuipers E.J., Klinkenberg-Knol E.C., et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997, 92:1997-2000.
33. Breuer T., Halaty H.M., Graham D.Y. The epidemiology of H. pylori-associated gastroduodenal disease. The immunobiology of H. pylori from pathogenesis to prevention 1997, 1-14. Lippincott-Raven, Philadelphia. P. Ernst, P. Michetti, P.D. Smith (Eds.).
34. Forman D., Graham D.Y. Review article: impact of Helicobacter pylori on society: role for a strategy of 'search and eradicate. Aliment Pharmacol Ther 2004, 19(Suppl 1):17-21.
35. Parkin D.M., Pisani P., Munoz N. The global burden of cancer. Cancer Surv 1999, 33:5-33.
36. Kim S., Park Y., Kim N., et al. Effect of Helicobacter pylori eradication on functional dyspepsia. JNeurogastroenterol Motil 2013, 19:233-243.
37. Mazzoleni L., Sander G., Francesconi C., et al. Helicobacter pylori eradication in functional dyspepsia. Arch Intern Med 2011, 171:1929-1935.
38. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, (2). CD002096.
39. Den Hollander W., Sostres C., Kuipers E., et al. Helicobacter pylori and nonmalignant disease. Helicobacter 2013, 18(Suppl 1):24-27.
40. Zhao B., Zhao J., Cheng W.F., et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow up. J Clin Gastroenterol 2014, 48(3):241-247.
41. Mönkemüller K., Malfertheiner P. Drug treatment of functional dyspepsia. World J Gastroenterol 2006, 12(17):2694-2700.
42. Futagami S., Shimpuku M., Song J.M., et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion 2012, 86(2):114-121.
43. Moayyedi P., Shelly S., Deeks J.J., et al. WITHDRAWN: pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011, (2). CD001960.
44. Van Zanten S.V., Armstrong D., Chiba N., et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol 2006, 101:2096-2106.
45. Meineche-Schmidt V., Christensen E., Bytzer P. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care: a randomized, placebo-controlled study. Aliment Pharmacol Ther 2011, 33:41-49.
46. Talley N.J., Meineche-Schmidt V., Pare P., et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998, 12:1055-1065.
47. Bolling-Sternevald E., Lauritsen K., Talley N.J., et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?. Aliment Pharmacol Ther 2003, 18:117-124.
48. Peura D.A., Kovacs T.O., Metz D.C., et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004, 116:740-748.
49. Hsu Y.C., Liou J.M., Yang T.H., et al. Proton pump inhibitor therapy versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?. JGastroenterol 2011, 46(2):183-190.
50. Hiyama T., Yoshihara M., Matsuo K., et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. JGastroenterol Hepatol 2007, 22:304-310.
51. Yoshii K., Hirayami M., Nakamura T., et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. JPharm Sci 2011, 100:4965-4973.
52. Matsueda K., Hongo M., Tack J., et al. Aplacebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012, 61(6):821-828.
53. Kusunoki H., Haruma K., Manabe N., et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012, 24(6):540-545.
54. Altan E., Masaoka T., Farré R., et al. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome. Expert Rev Gastroenterol Hepatol 2012, 6(5):533-544.
55. Hojo M., Miwa H., Yokoyama T., et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. JGastroenterol 2005, 40(11):1036-1042.
56. Passos M.C., Duro D., Fregni F. CNS or classic drugs for the treatment of pain in functional dyspepsia? A systematic review and meta-analysis of the literature. Pain Physician 2008, 11:597-609.
57. Grover M., Drossman D.A. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008, 8:715-723.
58. Braak B., Klooker T.K., Wouters M.M., et al. Randomized clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011, 34:638-648.
59. Moshiree B., Barboza J., Talley N.J. An update on current pharmacotherapy options for dyspepsia. Expert Opin Pharmacother 2013, 14:1737-1753.
60. Van Kerkhoven L.A., Laheij R.J., Aparicio N., et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008, 6:746-752.
61. Talley N.J., Locke G.R., Herrick L.M., et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012, 33(3):523-533.
62. Tack J., Janssen P., Masaoka T. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012, 10(11):1239-1245.
63. Coffin B., Bortolloti C., Bourgeois O., et al. Efficacy of a smiethicone, activated charcoal and magnesium oxide combination (Carbosymag) in functional dyspepsia: results of a general practice-based randomized trial. Clin Res Hepatol Gastroenterol 2011, 35(6-7):494-499.
64. Faramarzi M., Azadfallah P., Book H.E., et al. Arandomized controlled trial of brief psychoanalytic psychotherapy in patients with functional dyspepsia. Asian J Psychiatr 2013, 6(3):228-234.
65. Haug T., Wilhelmsen I., Svebak S., et al. Psychotherapy in functional dyspepsia. JPsychosom Res 1994, 38:735-744.
66. Hamilton J., Guthrie E., Creed F., et al. Arandomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119:662-669.
67. Soo S., Forman D., Delaney B., et al. Asystematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004, 99:1817-1822.
68. Xu S., Zha H., Hou X., et al. Electroacupuncture accelerates solid gastric emptying in patients with functional dyspepsia. Gastroenterology 2004, 126:A-437.